rubitecan structure 
             | 
        Common Name | rubitecan | ||
|---|---|---|---|---|
| CAS Number | 91421-42-0 | Molecular Weight | 393.350 | |
| Density | 1.6±0.1 g/cm3 | Boiling Point | 816.3±65.0 °C at 760 mmHg | |
| Molecular Formula | C20H15N3O6 | Melting Point | 182-186ºC | |
| MSDS | USA | Flash Point | 447.5±34.3 °C | |
            Use of rubitecanRubitecan (RFS 2000), a camptothecin derivative, is an orally active topoisomerase I inhibitor with broad antitumor activity, and induces protein-linked DNA single-strand breaks, thereby blocking DNA and RNA synthesis in dividing cells[1][2][3].  | 
    
| Name | 9-Nitrocamptothecin | 
|---|---|
| Synonym | More Synonyms | 
| Description | Rubitecan (RFS 2000), a camptothecin derivative, is an orally active topoisomerase I inhibitor with broad antitumor activity, and induces protein-linked DNA single-strand breaks, thereby blocking DNA and RNA synthesis in dividing cells[1][2][3]. | 
|---|---|
| Related Catalog | |
| Target | 
                                    
                                     Topoisomerase I[1]  | 
                            
| In Vitro | Rubitecan (RFS 2000) inhibits U-CH1, U-CH2, and CCL4 cells with IC50s 0.32, 0.83, and 7.7 µM, respectively[4]. | 
| References | 
                                       [3]. Rubitecan  | 
                            
| Density | 1.6±0.1 g/cm3 | 
|---|---|
| Boiling Point | 816.3±65.0 °C at 760 mmHg | 
| Melting Point | 182-186ºC | 
| Molecular Formula | C20H15N3O6 | 
| Molecular Weight | 393.350 | 
| Flash Point | 447.5±34.3 °C | 
| Exact Mass | 393.096100 | 
| PSA | 127.24000 | 
| LogP | 1.38 | 
| Vapour Pressure | 0.0±3.1 mmHg at 25°C | 
| Index of Refraction | 1.762 | 
| Storage condition | Room temp | 
| Personal Protective Equipment | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter | 
|---|---|
| RIDADR | NONH for all modes of transport | 
| RTECS | UQ0493300 | 
| Precursor 6 | |
|---|---|
| DownStream 4 | |
| 
                                    
                                    Effect of injection routes on pharmacokinetics and lactone/carboxylate equilibrium of 9-Nitrocamptothecin in rats.
                                    
                                    
                                     Int. J. Pharm. 340(1-2) , 29-33, (2007) Pharmacokinetics and lactone/carboxylate equilibrium of 9-Nitrocamptothecin (9-NC) were compared after intravenous (i.v.) and intramuscular (i.m.) injection at a dose of 1.5mg/kg 9-NC solution. The co...  | 
                                |
| 
                                    
                                    Effect of phospholipid composition on characterization of liposomes containing 9-nitrocamptothecin.
                                    
                                    
                                     Drug Dev. Ind. Pharm. 32(6) , 719-26, (2006) 9-Nitrocamptothecin (9-NC), a newly developed camptothecin derivative, had poor solubility in any pharmaceutically acceptable solvents. One way of improving the solubility is to formulate the drug int...  | 
                                |
| 
                                    
                                    Sequential oral 9-nitrocamptothecin and etoposide: a pharmacodynamic- and pharmacokinetic-based phase I trial.
                                    
                                    
                                     Mol. Cancer Ther. 5(8) , 2130-7, (2006) Resistance to topoisomerase (topo) I inhibitors has been related to down-regulation of nuclear target enzyme, whereas sensitization to topo II inhibitors may result from induction of topo II by topo I...  | 
                                
| rubitecan | 
| MFCD06656294 | 
| 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 4-ethyl-4-hydroxy-10-nitro-, (4S)- | 
| PYRIDOXINE 3,4-DIPALMITATE | 
| 9-nitro-20(s)-camptothecin | 
| 1H-PYRANO[3',4':6,7]INDOLIZINO[1,2-B]QUINOLINE-3,14(4H,12H)-DIONE,4-ETHYL-4-HYDROXY-10-NITRO-, (4S)- | 
| (4S)-4-Ethyl-4-hydroxy-10-nitro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione | 
| Orathecin |